97 results about "Proton pump" patented technology

Veterinary pharmaceutical compositions for direct systemic introduction, also known as DSI pharmaceutical compositions. One veterinary pharmaceutical composition for direct systemic introduction includes about 10-17 dry mass % bovine gelatin; about 10-17 dry mass % mannitol; about 0-1 dry mass % of a surfactant; and about 65-80 dry mass % of the active pharmaceutical ingredient which is a proton pump inhibitor. A method of manufacturing a veterinary pharmaceutical composition for direct systemic introduction includes combining one or more pharmacologically inactive compounds to form a first solution; using one or more surfactants to form a second solution; adding an active pharmaceutical ingredient to the second solution to form a first mixture; adding the first solution to the first mixture to form a pre-formulation; freezing the pre-formulation; and lyophilizing the pre-formulation.

The invention relates to the technical field of biological medicine, and discloses a formula of compound probiotic enzyme powder for promoting gastrointestinal microecological balance and nutrient absorption, by constructing a cross feeding system of bifidobacteria, lactobacillus and butyric acid bacteria and combining a stomach-intestine stage enzyme activity gradient adaptation strategy and a microenvironment response type double-layer embedding technology, the gastrointestinal microecological balance and nutrient absorption can be promoted, and the gastrointestinal microecological balance and nutrient absorption can be promoted. And cross-scale synergy of flora metabolism, substrate conversion and targeted release is realized. Wherein the sodium alginate-pectin composite embedding structure forms a pH buffer micro-area in a gastric acid environment, and proton pump gene expression of the acid-resistant strain is synchronously triggered; the prebiotics compounding and step-by-step enzymolysis process breaks through a closed-loop path of fiber degradation-flora proliferation-short-chain fatty acid generation. Compared with a traditional single-strain intervention scheme, the method has the advantages that double limitations of flora function splitting and process isolation are broken through, and systematic technical advantages are formed in the aspects of improving flora colonization stability, enhancing metabolite conversion efficiency and inhibiting pathogenic bacterium colonization.

Use of a proton pump regulator in the preparation of a reagent for preventing and / or treating diseases, wherein the proton pump regulator regulates ATP6V1B2 and / or a functional active fragment thereof, and the diseases comprise strokes.

The invention discloses a sequential anti-tumor strategy based on combination of improved tumor microenvironment (TME) and CAR T and application of the sequential anti-tumor strategy, belongs to the technical field of biological medicine, and particularly relates to a sequential anti-tumor strategy based on combination of improved tumor microenvironment (TME) and CAR T. According to the strategy, tumor fibrosis and an acidic microenvironment are improved at the same time by applying a tumor-associated fibroblast (CAF) targeted drug and a proton pump inhibitor, and then sequential injection of CAR T is performed for combined treatment of solid tumors. Wherein the CAF targeting drug is selected from all-trans retinoic acid, calcipotriol, losartan and minetil, the proton pump inhibitor is selected from lansoprazole, omeprazole, pantoprazole, rabeprazole and esomeprazole, and the CAR T receptor or ligand is selected from mesothelin, protein tyrosine kinase 7, NKG2D, CD47, B7-H3, MUC1 and HER2; the sequential administration strategy firstly destroys a compact physical barrier of a tumor microenvironment, improves acidity of a tumor site, ensures infiltration, survival and proliferation of CAR T at the tumor site, and then utilizes specificity of CAR T to inhibit growth of solid tumors in a targeted manner, especially triple negative breast cancer with a high malignancy degree.

The embodiment of the invention discloses a primer group and application. Specific primers are designed for a UreA gene, a GyrA gene, a 23SrRNA gene, a PbP1 gene, a 16SrRNA gene, a porD gene, a CagA gene, a vacA gene, a CYP2C19 * 2 gene, a CYP2C19 * 3 gene, a CYP2C19 * 17 gene and mutation sites on the basis of a nucleic acid mass spectrometry technology, the helicobacter pylori detection kit has the advantages of high sensitivity and high accuracy, and helicobacter pylori identification, antibiotic sensitivity / drug resistance detection and virulence gene typing can be quickly and efficiently carried out; the method for detecting the metabolic type of the proton pump inhibitor has a good application prospect.

The invention discloses a preparation method of a proton pump inhibitor intermediate, which comprises the following steps: (1) carrying out condensation reaction on 2-mercapto-5-aminobenzimidazole and 2, 5-dimethoxytetrahydrofuran in an acetic acid medium; (2) after the reaction is finished, adding a solvent 1 into the obtained reaction liquid, and separating out a wet product solid; (3) dissolving the wet product solid obtained in the step (2) in a solvent 2, and then adjusting the pH value of the reaction solution to 10.5-12.5 by using an alkaline solution; then adding a solvent 3 to perform extraction operation on the reaction liquid, and collecting an organic phase; and (4) concentrating and drying: concentrating and drying the organic phase obtained in the step (3) to obtain the proton pump inhibitor intermediate 5-(1H-pyrrole-1-yl)-2-mercaptobenzimidazole, and the proton pump inhibitor intermediate obtained by the invention has high yield, high content and good appearance.

A heterobicyclic derivative represented by chemical formula (I), according to the present invention, has a reversible proton pump inhibitory effect, and thus the heterobicyclic derivative and a pharmaceutical composition comprising same can be effectively used as a therapeutic agent for diseases associated with gastric acid secretion, particularly, as P-CAB.

The present disclosure relates to storage-stable proton pump inhibitor (PPI) systems comprising a therapeutically effective amount of a PPI or a pharmaceutically acceptable salt thereof, such as omeprazole or a pharmaceutically acceptable salt thereof, which are constituted with water prior to administration. The present disclosure also relates to oral pharmaceutical suspensions comprising water, a therapeutically effective amount of a PPI or a pharmaceutically acceptable salt thereof, such as omeprazole or a pharmaceutically acceptable salt thereof, and one or more buffering agents.

The invention provides a primer combination for detecting helicobacter pylori and application of the primer combination. The primer combination is used for strain identification of the helicobacter pylori and detection of gastric cancer risk sites, antibiotic resistance sites, virulence genotyping and human proton pump inhibitor drug metabolism. On the basis of multiple PCR and targeted high-throughput sequencing technologies, specific targeted amplification primers are designed and mixed, so that the helicobacter pylori identification can be completed, gastric cancer risk sites, antibiotic resistance genes, virulence typing and human proton pump inhibitor drug metabolism genes of the helicobacter pylori can be detected, and finally, the helicobacter pylori can be detected. A quantitative algorithm of approximate concentration of helicobacter pylori is also introduced into the system, so that more sensitive, accurate and comprehensive detection of helicobacter pylori is realized.

The invention belongs to the technical field of proton pump inhibition medicine preparations, and relates to a rabeprazole sodium enteric-coated tablet and a preparation method thereof. The technical problems that an existing rabeprazole sodium enteric-coated tablet is insufficient in stability, lagged in dissolution and the like are solved. The enteric-coated tablet consists of a tablet core and an enteric-coated coating layer wrapped outside the tablet core, wherein the tablet core comprises auxiliary materials such as rabeprazole sodium, a filling agent, an adhesive, a stable dissolution promoter and the like; the enteric coating layer comprises an enteric coating material, a plasticizer, an anti-sticking agent and a solvent. Through the synergistic effect of the compound stabilizer and process control, the stability and dissolution performance of the enteric-coated tablet are synergistically improved, meanwhile, the production process is simplified, and the preparation method is suitable for industrial application.

The invention relates to the technical field of biological engineering, and discloses a method for enhancing the urea circulation function of a 3D biological printing liver organ, which comprises the following steps: a cell preparation step: through a genetic engineering technology, enabling mitochondria of liver cells to express a light-driven proton pump, and enabling intracellular expression of a fluorescent probe for reporting ammonia concentration; an organ construction step: mixing the cells with hydrogel to prepare bio-ink, and constructing a three-dimensional liver organ by using a 3D biological printing technology; a system integration step: placing the liver organ in an integrated photoelectric regulation and control system capable of monitoring a fluorescence signal in real time and applying illumination; and a closed-loop enhancement step: the system monitors the ammonia concentration in real time, and when the ammonia concentration exceeds a preset threshold value, illumination is automatically applied to activate the proton pump, so that the urea circulation function is enhanced as required. Through closed-loop light control and a subcellular organelle energy channel, on-demand, efficient and high-temporal-spatial-resolution dynamic enhancement of the liver organ urea circulation function is achieved.

The present invention relates to a novel pyrrole derivative compound or a pharmaceutically acceptable salt thereof. In addition, the present invention relates to a pharmaceutical composition for potassium-competitive inhibition of gastric acid secretion and a pharmaceutical composition for preventing or treating diseases caused by gastric acid secretion disorder, the pharmaceutical composition containing the novel pyrrole derivative compound or a pharmaceutically acceptable salt thereof as an active component. The pyrrole derivative compound or the like according to the present invention is a potassium-competitive acid blocker (PCAB) and has an excellent H+ / K+ adenosine triphosphatase (ATPase) (proton pump) inhibition effect, and is thus widely used as a therapeutic agent for diseases caused by gastric acid secretion disorder.

This invention is applied in the field of medicine, namely in endocrinology, and can be used in the treatment of type 1 diabetes. The invention proposes a combination containing a dipeptidyl peptidase 4 (DPP-4) inhibitor, a proton pump inhibitor (PP1), and γ-aminobutyric acid or γ-aminobutyric acid receptor agonist. This unique combination and dosage of drugs leads to the regeneration (recovery) of pancreatic β-cells, which occurs with a dramatic reduction in insulin requirements up to a total cessation of insulin in some individuals and is intended for the treatment of type 1 diabetes mellitus.

Disclosed are methods and compositions for treating cell proliferative diseases and disorders including cancers such as glioblastoma. The disclosed methods and compositions may utilize or comprise one or more modulators of the bioelectric state of cells, such as, one or more potassium channel activators; a sodium channel inhibitor combined with an mTOR inhibitor; a sodium channel inhibitor combined with a proton pump inhibitor; a calcium channel inhibitor combined with an mTOR inhibitor; a proton pump inhibitor combined with an alkylating agent; or a combination of at least one potassium channel activator and one or more of an alkylating agent, calcium channel inhibitor, corticosteroid, mTOR inhibitor, proton pump inhibitor, and / or sodium channel inhibitor.

A pharmaceutical formulation according to some embodiments comprises: an immediate-release part for eluting an active ingredient in a pH-independent manner; and an enteric part for eluting the active ingredient in a pH-dependent manner, wherein the active ingredient may comprise a proton pump inhibitor, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof. Some embodiments of the present invention enable immediate absorption of drugs while maintaining prolonged pharmacological efficacy.

Helicobacter pylori (HP) is a chronic bacterium that infects the gastric mucosa. It is widespread in the general population, with an infection rate between 55% and 70%. HP is closely related to gastric ulcers and gastritis. Western medicine treatment for HP infection is relatively complex, including bismuth substituents and proton pump inhibitors plus two antibiotics. Gastric ulcers and gastritis are common digestive system diseases. Compound 1, "Exterminate the Ghost," is a traditional Chinese medicine composition mainly composed of Coptis chinensis, plus Scutellaria baicalensis and Fraxinus chinensis, which can eradicate HP. Compound 2, "Ulcer Relief," is a traditional Chinese medicine composition mainly composed of Coptis chinensis, plus Rheum palmatum and Bletilla striata, which can cure gastric ulcers. Compound 3, "Gasitis Relief," is a traditional Chinese medicine composition mainly composed of Coptis chinensis, plus Glycyrrhiza uralensis or Taraxacum mongolicum, made into a tea bag, which can cure chronic gastritis.

The present invention relates to a pharmaceutical composition comprising: a first unit comprising acetylsalicylic acid or a pharmaceutically acceptable salt thereof; and a second unit comprising a proton pump inhibitor. The pharmaceutical composition according to the present invention is divided into the first unit and the second unit, thus preventing direct contact between the drugs. Therefore, stability is achieved and the effect on the individual release of the respective drugs is minimized, and thus improved elution is exhibited.

A tricyclic derivative represented by chemical formula (I), of the present invention, has a reversible proton pump inhibitory effect, and thus the tricyclic derivative and a pharmaceutical composition comprising same can be effectively used as a therapeutic agent for diseases associated with gastric acid secretion, particularly, as P-CAB.

The present invention relates to a pharmaceutical composition a first comprising: unit comprising acetylsalicylic acid or a pharmaceutically acceptable salt thereof; and a second unit comprising a proton pump inhibitor. The pharmaceutical composition according to the present invention is divided into the first unit and the second unit, thus preventing direct contact between the drugs. Therefore, stability is achieved and the effect on the individual release of the respective drugs is minimized, and thus improved elution is exhibited.

A fusion protein comprises (1) a first moiety that targets and orients the fusion protein to mitochondria inner membrane and (2) a second moiety that provides light-activated proton pump function when integrate into the mitochondria inner membrane. The fusion protein can be used for modulating hypoxia signaling in a subject, revitalizing cells, modulating T cell function, improving feed efficiency, prolonging lifespan and treating cancer.

The present invention relates to a protein complex that uses electric current to provide biological useful energy to a cell used in biotechnology. The present invention also relates to a method for producing a protein complex as microbial electricity-driven proton pump (MEPP) for a cell and genetically modified host cells used for the production of the energy-delivering protein complex MEPP.

Powder composition for oral suspension comprising a two phase powder mixture, where the first phase is in powder form comprising a Proton Pump Inhibitor (e.g. omeprazole) or pharmaceutically acceptable salts thereof in an amount of 0.01-7.5 % by weight, at least one diluent (e.g. mannitol), a first buffering agent (e.g. sodium hydrogen carbonate), a binding agent (e.g. xanthan gum), and the second phase is in powder form comprising a second buffering agent, a viscosity enhancer (e.g. sodium alginate) in the range 0.0010 %w / w to 2.0 wt.%, at least one diluent; at least one preservative (e.g. sodium benzoate, sodium methyl para hydroxy benzoate), a diluent, and an excipient (e.g. a flavour). Preferably, the second buffering agent is a carbonate or hydrogen carbonate. Preferably, the D50 of the omeprazole, if present, is 1.5-5.5 microns. The composition may be used in the treatment of erosive oesophagitis, gastroesophageal reflux, gastric ulcers etc.

The present invention relates to clear stable ready to use compositions of Proton pump inhibitors, in particular Omeprazole or Esomeprazole or salts thereof. The invention also provides a process to prepare these compositions.

The present invention relates to a pyrrole derivative or a pharmaceutically or sitologically acceptable salt thereof, and composition for prevention, amelioration or treatment of gastrointestinal disorders comprising same as active ingredient. Through the results, it can be confirmed that the pharmacokinetic parameters, oral bioavailability and storage stability of the compound of the present invention are remarkably improved due to deuteration of the terminal methylamine moiety. The pyrrole derivative or the pharmaceutically or sitologically acceptable salt thereof the present invention exhibits excellent anticancer activity in addition to excellent proton pump inhibitory activity, and has improved pharmacokinetic parameters and chemical stability, and thus can be effectively used in the prevention, amelioration or treatment of gastrointestinal disorders, including gastric cancer.

This invention provides a method for preparing a proton pump inhibitor thioether intermediate. The method involves reacting 3,5-dimethyl-4-methoxy-2-pyridinemethanethiol as a raw material with paraformaldehyde to obtain an intermediate, which is then further reacted with 4-methoxy-o-phenylenediamine, followed by post-treatment to obtain omeprazole thioether. This preparation method is novel, simple to operate, produces a high-purity product, and is suitable for industrial production.

The present invention discloses a method for analyzing the liver toxicity differences between proton pump inhibitors and H2 receptor antagonists based on network toxicology. The method of the present invention comprises the following steps: mining the action targets of drugs and liver toxicity disease risk genes in a database, constructing a protein interaction network of the drug-induced liver injury disease module DILI, and performing GO biological function and KEGG pathway enrichment analysis on the risk genes; overlapping the drug targets and the DILI disease module and analyzing the drug liver toxicity mechanism; calculating the proximity degree between the drug and the DILI disease module by using a network proximity strategy; and finally performing molecular docking on the drug molecule and the core target. The method of the present invention reveals that H2 receptor antagonists have stronger liver toxicity than proton pump inhibitors, explores the mechanism of potential liver injury of drugs, and provides a reference for the subsequent liver toxicity research of drugs.

The invention discloses a new application of a proton pump inhibitor. The proton pump inhibitor realizes treatment on related diseases and enhances the treatment effect by promoting endocytosis of extracellular vesicles. The proton pump inhibitor is used for enhancing anti-tumor immunity; the proton pump inhibitor is used for relieving pd-1 drug resistance in tumor treatment; the proton pump inhibitor is used for enhancing the drug delivery function of the extracellular vesicles; the proton pump inhibitor is used for removing extracellular vesicles. The invention finds that the proton pump inhibitor can enhance anti-tumor immunity, reduce drug resistance, enhance the delivery effect of extracellular vesicles on therapeutic drugs and reduce side effects of the drugs. The invention provides a pharmaceutical composition containing the proton pump inhibitor, and the pharmaceutical composition has a wide application prospect.

An aspect provides a pharmaceutical composite formulation containing: a first layer comprising a proton pump inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient, a disintegrant, and a binder; and a second layer comprising, as an active ingredient, an antacid selected from magnesium hydroxide, magnesium oxide, or a mixture thereof.

Disclosed herein are liquid diluents, formulations, and kits for preparing reconstituted suspensions of a proton pump inhibitor (e.g., omeprazole). The present disclosure also provides formulations for liquid diluents that do not have a tendency for gel formation following exposure to freeze-thaw cycles.

The application discloses a sequential anti-tumor strategy based on improvement of tumor microenvironment (TME) combined with CAR T and application thereof, and belongs to the technical field of biological medicine, which simultaneously improves tumor fibrosis and acid microenvironment by applying tumor-related fibroblast (CAF) targeting drugs and proton pump inhibitors, and sequentially injects CAR T combined therapy for solid tumors, wherein the CAF targeting drugs are selected from tretinoin, calcipotriol, losartan and minnelide, the proton pump inhibitors are selected from lansoprazole, omeprazole, pantoprazole, rabeprazole and esomeprazole, and the CAR T receptor or ligand is selected from mesothelin, protein tyrosine kinase 7, NKG2D, CD47, B7-H3, MUC1 and HER2; the sequential administration strategy first destroys the dense physical barrier of the tumor microenvironment, improves the acidity of the tumor site, ensures the infiltration, survival and proliferation of CAR T at the tumor site, and then targets and inhibits the growth of solid tumors, especially high-malignancy triple-negative breast cancer, by using the specificity of CAR T.